Highly Effective Treatment of Skull Base Chordoma with Carbon Ion Irradiation Using a Raster Scan Technique in 155 Patients: First Long-term Results
Overview
Authors
Affiliations
Background: The current study was conducted to evaluate the long-term results of irradiation with carbon ions in a raster scanning technique in patients with skull base chordomas.
Methods: Between 1998 and 2008, a total of 155 patients (76 men and 79 women) with a median age of 48 years (range, 15 years-85 years) were irradiated with carbon ions using a raster scan technique. The irradiation was performed at the Society for Heavy Ion Research in Darmstadt, Germany. The median total dose was 60 gray (relative biological effectiveness) at 3 gray (relative biological effectiveness) per fraction. The median boost planning target volume was 70 mL (range, 2 mL-294 mL). Local control (LC) and overall survival (OS) were evaluated using the Kaplan-Meier method, whereas long-term toxicity was evaluated via questionnaires.
Results: The median follow-up was 72 months (range, 12 months-165 months). All patients had residual macroscopic tumors at the initiation of radiotherapy. The authors observed 55 local recurrences during follow-up, as well as systemic disease progression in 4 patients. The resulting 3-year, 5-year, and 10-year LC rates were 82%, 72%, and 54%, respectively, whereas the 3-year, 5-year, and 10-year OS rates were 95%, 85%, and 75%, respectively. Age <48 years and a boost volume >75 mL were associated with a significantly improved LC and OS. Primary treatment resulted in a significantly better OS probability. No higher late toxicity could be detected after carbon ion treatment.
Conclusions: Carbon ion therapy appears to be a safe and effective treatment for patients with skull base chordoma, resulting in high LC and OS rates.
Lemaeva A, Gulidov I Sovrem Tekhnologii Med. 2025; 15(5):44-52.
PMID: 39967912 PMC: 11832067. DOI: 10.17691/stm2023.15.5.05.
Rodrigues A, Tos S, Shaaban A, Mantziaris G, Trifiletti D, Sheehan J Neurosurg Rev. 2024; 47(1):893.
PMID: 39644344 PMC: 11625079. DOI: 10.1007/s10143-024-03117-1.
Orlandi E, Barcellini A, Vischioni B, Fiore M, Vitolo V, Iannalfi A Cancers (Basel). 2023; 15(20).
PMID: 37894434 PMC: 10605728. DOI: 10.3390/cancers15205068.
Holtzman A, Seidensaal K, Iannalfi A, Kim K, Koto M, Yang W Cancers (Basel). 2023; 15(20).
PMID: 37894388 PMC: 10605639. DOI: 10.3390/cancers15205021.
Endo M Radiol Phys Technol. 2023; 16(4):443-470.
PMID: 37882992 DOI: 10.1007/s12194-023-00748-9.